CurrentCareSourcePolicy N/A

Transplantation Nulojix Utilization Management Medical Policy

Defines prior-authorization and medical necessity criteria for Nulojix (belatacept) intravenous infusion for prevention of organ rejection in transplant recipients, primarily kidney transplant patients, and applies to CareSource-covered members in North Carolina.

Policy Summary

PayerCareSource

PolicyTransplantation Nulojix Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateAug 21, 2024

Key ActionObtain prior authorization and document EBV seropositivity and transplant specialist prescribing or consultation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 yrstandard approval duration

≤10 mg/kgmax per-dose limit

≤4induction doses

EBV+safety prerequisite

Not livercontraindicated organ

Coverage Criteria for Nulojix (belatacept)

Policy Summary

PayerCareSource

PolicyTransplantation Nulojix Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateAug 21, 2024

Key ActionObtain prior authorization and document EBV seropositivity and transplant specialist prescribing or consultation.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA-Approved Indication — Kidney Transplantation Prophylaxis of Organ Rejection (Initial/De novo)

Approve for 1 year if the patient meets ALL of the following (A, B, and C):

Kidney transplant criteria: A) Patient is ≥ 18 years of age; B) Patient is Epstein-Barr virus (EBV) seropositive; AND C) Nulojix is prescribed by or in consultation with a transplant specialist physician or a physician associated with a transplant center.

Approval duration: 1 year.

Dosing limits: A) Each individual dose must not exceed 10 mg/kg administered by intravenous infusion; AND B) Nulojix is administered no more than four times in the first 4 weeks (day of transplant, day 5, end of week 2, and end of week 4), then no more frequently than once every 4 weeks.<= 10 mg/kg per dose; induction: ≤4 doses in first 4 weeks; maintenance: once every 4 weeks

Doses approved per regimen for 1 year.

Other Uses with Supportive Evidence — Solid Organ Transplantation Other Than Kidney (Patients Currently Receiving Nulojix)

Approve for 1 year if the patient meets ALL of the following (A, B, and C):

Non-kidney solid organ continuation criteria: A) Patient is ≥ 18 years of age; B) Patient is Epstein-Barr virus (EBV) seropositive; AND C) Nulojix is prescribed by or in consultation with a transplant specialist physician or a physician associated with a transplant center.

Intended for patients currently receiving Nulojix for other solid organs; approval duration: 1 year.

Dosing limits (other organs): A) Each individual dose must not exceed 10 mg/kg administered by intravenous infusion; AND B) Nulojix is administered no more than four times in the first 4 weeks (day of transplant, day 5, end of week 2, and end of week 4), then no more frequently than once every 4 weeks.<= 10 mg/kg per dose; induction: ≤4 doses in first 4 weeks; maintenance: once every 4 weeks

Policy mirrors kidney dosing schedule for continuation use.

Use in liver transplant recipients is not recommended. Nulojix carries a boxed warning citing increased risk of graft loss and death observed in clinical trials of liver transplant patients; because of these safety findings, coverage is not recommended for liver transplantation and for circumstances not specifically listed in the Recommended Authorization Criteria.

Use in EBV seronegative or unknown EBV status patients is not recommended and is an absolute contraindication. The product labeling requires that Nulojix only be used in individuals who are EBV seropositive because seronegativity or unknown EBV status substantially increases the risk of post‑transplant lymphoproliferative disorder. For safety reasons, use in liver transplant recipients is also considered unsafe and is not recommended.

Dosing and Coding Rules

inv-05: Dose divisibility

Dose divisibilityPrescribed dose must be evenly divisible by 12.5 mg.

RationaleUse of higher than recommended doses or more frequent administration is not recommended due to increased risk of post-transplant lymphoproliferative disorder and serious CNS infections.

Weight basisDose is based on actual body weight at the time of transplantation.

inv-06: Weight change adjustment

Weight-change dosing ruleDo not modify dose unless the patient’s weight changes by ≥ 10%.

Dose timingDose is calculated from actual body weight at time of transplantation and maintained unless weight threshold met.

DocumentationWeight should be documented to justify any dose adjustment per policy guidance.

Provider Actions, Authorizations, and Review Requirements

Prior Authorization

Prior Authorization Recommended

Prior authorization is recommended for medical benefit coverage of Nulojix. Approval is recommended if the patient meets the policy's specified criteria and dosing for the FDA‑approved indication (kidney transplant prophylaxis). Requests for doses outside the documented dosing will be reviewed case‑by‑case. All approvals are provided for the duration specified in the policy. Because of the specialized skills required for evaluation, diagnosis, and monitoring, Nulojix must be prescribed by or in consultation with a physician who specializes in transplant care or is associated with a transplant center.

Prior authorization recommended; approvals per policy criteria and dosing
Dose-exception requests reviewed by clinician (Medical Director or Pharmacist)
Approvals issued for specified duration; extended approvals allowed if criteria continue to be met
Must be prescribed by or in consultation with a transplant specialist or physician associated with a transplant center

Note

Guideline Context (No Formal Step Therapy)

Clinical guidelines referenced in the policy endorse standard transplant immunosuppression approaches (e.g., use of a calcineurin inhibitor such as tacrolimus and an anti-proliferative agent such as mycophenolate, with or without corticosteroids). The policy does not impose a formal step‑therapy sequence; rather, it references guideline-based standard-of-care regimens and assesses Nulojix use against the FDA indication and safety considerations.

No formal step therapy requirement in this policy — guideline context only
Policy aligns with KDIGO and other transplant guidance recommending calcineurin inhibitor + antiproliferative agent ± corticosteroids for maintenance

Documentation Required

Prescriber and Review Requirements

Nulojix must be prescribed by or in consultation with a transplant specialist physician or a physician associated with a transplant center. This requirement supports appropriate patient selection, dosing, and monitoring for serious risks associated with therapy.

Prescriber requirement: transplant specialist or physician associated with a transplant center
Ensures specialist oversight for monitoring adverse events and long-term efficacy

Denial Risk

Triggers for Denial

Use of Nulojix in certain high‑risk populations or contexts is a safety concern and may preclude approval per the policy.

Not recommended for EBV seronegative or unknown EBV status patients (increased risk of post‑transplant lymphoproliferative disorder)
Not recommended for liver transplant recipients (increased risk of graft loss and death)
Coverage not recommended for indications or circumstances outside the policy's Recommended Authorization Criteria

Evaluation and Documentation Requirements

Documentation Required

Evaluation: confirm EBV seropositivity and specialist involvement

Document the patient's Epstein-Barr virus (EBV) serostatus prior to approval — the patient must be EBV seropositive. Also document that Nulojix was prescribed by or in consultation with a transplant specialist or physician associated with a transplant center.

Record EBV serology demonstrating seropositive status before approving Nulojix.
Include documentation of prescribing physician or documented consult with a transplant specialist/center.

Background

Nulojix (belatacept) is a selective T‑cell costimulation blocker indicated for prophylaxis of organ rejection in kidney transplant recipients when used as part of the indicated immunosuppressive regimen. Dosing is weight‑based, approvals are generally provided for 1 year, and individual doses must not exceed 10 mg/kg. Doses must be divisible by 12.5 mg, and dosing modifications are not made unless the patient’s weight changes by ≥ 10%. The labeling includes boxed warnings for post‑transplant lymphoproliferative disorder and for use in liver transplant recipients; because of these risks, Nulojix should only be used in patients who are EBV seropositive and per policy must be prescribed by or in consultation with a transplant specialist or transplant center physician.

OpenPayer

Transplantation Nulojix Utilization Management Medical Policy

Coverage Criteria for Nulojix (belatacept)

Patient Eligibility and Candidate Criteria

Dosing and Coding Rules

Provider Actions, Authorizations, and Review Requirements

Evaluation and Documentation Requirements

Center and Prescriber Requirements

Post-Transplant Coverage Duration and Follow-up

Definitions and Key Terms

Background

Contraindications